Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand
Albert M. Baehny will retire from Lonza Group following a transition period
Advertisement
Wolfgang Wienand joins Lonza Group as chief executive officer (CEO). Wolfgang succeeds Albert M. Baehny, who took on the role of CEO ad interim in October 2023 and was Chairman of the Board of Directors of Lonza from 2018 to May 2024. Albert will work with Wolfgang to ensure a smooth leadership handover before he retires from Lonza this summer.
Jean-Marc Huët, Chairman of the Board of Directors, Lonza, commented: “On behalf of the Board, I extend a warm welcome to Wolfgang as he joins Lonza. Wolfgang brings with him a wealth of CDMO experience, combined with deep strategic and scientific expertise. As Wolfgang joins, we look forward to an era of stable and structured growth under his leadership.”
Wolfgang Wienand, Chief Executive Officer, Lonza, commented: “Having worked in the CDMO industry for almost two decades, I always had great respect for Lonza’s ability to transform and grow at pace. It is a privilege to join this remarkable company as CEO. As I commence my journey with Lonza, we are embarking on a quest to meet and exceed the needs of our customers and their patients. I am greatly looking forward to working with the team to build on our strong foundations and create a strategy for us to deliver continued growth and reach our full potential.”
Since 2019, Wolfgang has held the role of CEO at Swiss CDMO, Siegfried. Wolfgang previously served as Chief Scientific Officer and then as Chief Strategy Officer in Siegfried’s executive leadership team. Prior to joining Siegfried in 2010, Wolfgang held a series of positions with increasing seniority at the German specialty chemicals company Evonik Industries.
Most read news
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Dr. Roland Durner becomes new CEO of Bioengineering AG

GDCh Award for Biocatalysis for Sebastian Gergel

Michael Grosse to succeed Joachim Kreuzburg as Chief Executive Officer of Sartorius AG - Grosse to take over as Group CEO on July 1, 2025

WACKER BIOSOLUTIONS under New Leadership - Susanne Leonhartsberger will leave the company at her own request at the end of 2024.

DMC Biotechnologies announces Dr. Jim Flatt as CEO - DMC seeking to transform how the world makes chemicals

Merck: New CEOs for Life Science and Healthcare business sectors and New Chief People Officer - Appointment of three internal senior executives ensures strategic continuity with a new era of leadership

CureVac appoints new CEO - Dr. Franz-Werner Haas to complete tenure as CEO by March 31, 2023

LenioBio announces new CEO - Founder will be stepping down as CEO

T-CURX announces senior leadership appointments - T-CURX completes formation of highly experienced clinical team to rapidly advance clinical translation of its next-generation CAR-T cell therapies

Samanta Cimitan Appointed Chief Executive Officer (CEO) at Celonic

BioGaia appoints Theresa Agnew as new CEO
